Radiation Dosimetry Aspects of Lu-177

被引:13
作者
Lassmann, Michael [1 ]
Eberlein, Uta [1 ]
机构
[1] Univ Wurzburg, Dept Nucl Med, Wurzburg, Germany
关键词
Lu-177; dosimetry; molecular radiotherapy; radiopeptide therapy;
D O I
10.2174/1874471008666150313104212
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review mainly focuses on the dosimetry methodology which includes consideration of the number and time points of scans, imaging methodology, methods for integrating time-activity curves and calculating absorbed doses. Lu-177-labelled compounds show many advantages for dosimetry assessments due to attractive physical properties which comprise low abundance of photons for sufficient post-therapy imaging, a clearly separated gamma peak at 208 keV, and a low range of beta particles. The most up-to-date results of absorbed dose calculations for the kidneys, bone marrow, and tumors are provided. The absorbed doses reported for radiopeptide therapies using Lu-177 labelled compounds taken from clinical studies show a high variability, presumably because of the different applied methodologies.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 28 条
[1]  
Be M.-M., 2004, TABLE RADIONUCLIDES, V2
[2]  
Bodei L., 2011, EUR J NUCL MED MOL I
[3]  
Cremonesi M, 2010, Q J NUCL MED MOL IM, V54, P37
[4]  
Cremonesi M, 2006, J NUCL MED, V47, P1467
[5]   Effect of Patient Morphology on Dosimetric Calculations for Internal Irradiation as Assessed by Comparisons of Monte Carlo Versus Conventional Methodologies [J].
Divoli, Antigoni ;
Chiavassa, Sophie ;
Ferrer, Ludovic ;
Barbet, Jacques ;
Flux, Glenn D. ;
Bardies, Manuel .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (02) :316-323
[6]   A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation [J].
Fernandez, Maria ;
Haenscheid, Heribert ;
Mauxion, Thibault ;
Bardies, Manuel ;
Kletting, Peter ;
Glatting, Gerhard ;
Lassmann, Michael .
MEDICAL PHYSICS, 2013, 40 (08)
[7]   Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas [J].
Forrer, Flavio ;
Oechslin-Oberholzer, Catharina ;
Campana, Benedetta ;
Herrmann, Richard ;
Maecke, Helmut R. ;
Mueller-Brand, Jan ;
Lohri, Andreas .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) :1045-1052
[8]   Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate [J].
Forrer, Flavio ;
Krenning, Eric P. ;
Kooij, Peter P. ;
Bernard, Bert F. ;
Konijnenberg, Mark ;
Bakker, Willem H. ;
Teunissen, Jaap J. M. ;
de Jong, Marion ;
van Lom, Kirsten ;
de Herder, Wouter W. ;
Kwekkeboom, Dik J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (07) :1138-1146
[9]   177Lu-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy [J].
Garkavij, Michael ;
Nickel, Mattias ;
Sjogreen-Gleisner, Katarina ;
Ljungberg, Michael ;
Ohlsson, Tomas ;
Wingardh, Karin ;
Strand, Sven-Erik ;
Tennvall, Jan .
CANCER, 2010, 116 (04) :1084-1092
[10]   Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy [J].
Garske, Ulrike ;
Sandstrom, Mattias ;
Johansson, Silvia ;
Sundin, Anders ;
Granberg, Dan ;
Eriksson, Barbro ;
Lundqvist, Hans .
ACTA ONCOLOGICA, 2012, 51 (01) :86-96